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Background: This study evaluated the characteristics of subependymal giant cell
astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC) entered into the
TuberOus SClerosis registry to increase disease Awareness (TOSCA).
Methods: The study was conducted at 170 sites across 31 countries. Data from patients
of any age with a documented clinical visit for TSC in the 12 months preceding enrollment
or those newly diagnosed with TSC were entered.
Results: SEGA were reported in 554 of 2,216 patients (25%). Median age at diagnosis
of SEGA was 8 years (range, <1–51), with 18.1% diagnosed after age 18 years. SEGA
growth occurred in 22.7% of patients aged ≤ 18 years and in 11.6% of patients aged >
18 years. SEGA were symptomatic in 42.1% of patients. Symptoms included increased
Jansen et al. SEGA in the TOSCA Natural History Registry
seizure frequency (15.8%), behavioural disturbance (11.9%), and regression/loss of
cognitive skills (9.9%), in addition to those typically associated with increased intracranial
pressure. SEGA were significantly more frequent in patients with TSC2 compared to
TSC1 variants (33.7 vs. 13.2 %, p < 0.0001). Main treatment modalities included surgery
(59.6%) and mammalian target of rapamycin (mTOR) inhibitors (49%).
Conclusions: Although SEGA diagnosis and growth typically occurs during childhood,
SEGA can occur and grow in both infants and adults.
Keywords: mTOR, registry, SEGA, TOSCA, tuberous sclerosis complex
INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal dominant
genetic disorder characterized by growth of hamartomas in
several organs, including the brain, kidneys, lungs, heart, eyes,
and skin (1). Subependymal giant cell astrocytomas (SEGA) are
benign, non-infiltrative brain lesions classified by the World
Health Organization as grade I, characteristically observed in
patients with TSC (2, 3). They are typically slow-growing
tumours composed of different cell lineages and are not purely
astrocytic in nature (4). Historically, SEGA diagnosis was based
on histology (5), but over time, diagnosis became imaging based.
In 2013, an international panel of experts defined the imaging
characteristics of SEGA as a lesion at the caudothalamic groove
with either a size of >1 cm in any direction or a subependymal
lesion at any location that has shown serial growth on consecutive
imaging regardless of size. Most SEGA show clear enhancement
after contrast administration. However, a growing subependymal
lesion even in the absence of enhancement should be considered
a SEGA (6). The prevalence of SEGA was previously reported
to range from 4 to 20% (2, 7–11). The studies mentioned were
based on relatively small patient numbers. In the largest series
by Adriaensen et al. evaluating 214 patients with TSC, SEGA
was defined as a subependymal lesion near the foramen of
Monro showing contrast enhancement after administration of
intravenous gadolinium. SEGA occurred in 20% of individuals in
this study and average maximum SEGA size was 11.4mm (range,
4–29mm) (2).
Although SEGA are histologically benign, their location
near the foramen of Monro and their tendency to grow can
lead to obstructive hydrocephalus with consecutive substantial
morbidity andmortality (12). Symptoms associated with growing
SEGA include those typically associated with raised intracranial
pressure (headaches, photophobia, diplopia, ataxia, seizures)
and/or detrimental effects on cognition and/or increased seizure
burden, learning, or behaviour (13). SEGA typically appear in the
first 2 decades of life, with a mean age at presentation below 18
years (14). However, there have been reports of SEGA detection
prenatally (as early as at 19 weeks gestation) (15–17), as well
as new diagnoses after 20 years of age (2, 18). There have been
prior reports suggesting that SEGA occur at a younger age in
patients with TSC2 mutations compared with those with TSC1
mutations (8, 19).
Currently, surgical resection and mammalian target of
rapamycin (mTOR) inhibitors are the recommended treatment
options for SEGA associated with TSC. Surgical resection should
be considered for acutely symptomatic SEGA, while either
surgical resection or medical treatment with mTOR inhibitors
may be considered for growing, but not acutely symptomatic
SEGA (20). However, surgical resection may be associated with
preoperative and postoperative complications, and incompletely
resected SEGA often tend to regrow (6, 14, 21). Everolimus,
an inhibitor of mTOR, the central pathway involved in the
pathophysiology of TSC, has been approved by the Food
and Drug Administration (FDA) and European Medicines
Agency (EMA) for patients with TSC-associated SEGA who
require therapeutic intervention, but are not candidates for
surgical resection (14). mTOR inhibitors have also shown
improvements in the other manifestations of TSC including
renal angiomyolipomas, epilepsy, lymphangioleiomyomatosis,
and facial angiofibromas (22–25).
Although substantial progress has been made in our
understanding of the biological and genetic basis of TSC in
the past decade, several questions, especially those related to
the natural history of the disease, remain unanswered. To
address this gap, the TOSCA (TuberOus SClerosis registry to
increase disease Awareness) registry was designed with the aim
of providing deeper insights into the manifestations of TSC and
its management. The baseline core data of the TOSCA registry
published previously provided understanding of the overall
manifestations and natural history of TSC (26). Here, we present
the clinical characteristics of SEGA in children and adults.
PATIENTS AND METHODS
TOSCA is a non-interventional, multicenter, international
natural history study conducted at 170 sites across 31 countries.
The study design and methodology of TOSCA have been
described in detail previously (27). In brief, between August 2012
and August 2014, patients of any age with a documented clinic
visit for TSC in the 12 months preceding enrollment or those
newly diagnosed with TSC were enrolled. General information
on patient background, such as demographic data, family history,
genotype, vital signs, prenatal history, clinical features of TSC
across all organ systems, comorbidities, and rare manifestations,
was collected at baseline and at regular visits scheduled at a
maximum interval of 1 year. Follow-up visits were scheduled
according to the standard practice of the site and as per the
treating physician’s best judgement. The data were recorded on
an electronic case report form (eCRF) that was accessed via a
secure web portal hosted by a contract research organization.
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Input of data was carried out by local investigators or their
deputies, and then independently checked by a network of
clinical research associates for accuracy and consistency using the
original local case records. The web portal has an explanatory
manual to guide the investigators.
Data collected specific to SEGA included tumour
characteristics such as presence of single or multiple SEGA,
clinical signs and symptoms associated with SEGA, and
management. Characteristics of SEGA according to the age at
consent were evaluated. The study also assessed the association
between genotype (TSC1 vs. TSC2) and SEGA characteristics
using Chi-square test or fisher exact test, and median test. Since
baseline data were collected prior to the 2013 international
consensus on SEGA definition, no specific inclusion criteria
were defined. The TOSCA cohort therefore reflects worldwide
clinical practice.
Given that the natural history study is exploratory in
nature, background and clinical parameters were reported with
descriptive statistics only. All eligible patients enrolled in the
TOSCA registry were considered for analysis. Categorical data
were reported as frequencies and percentages, and continuous
variables were expressed as mean (± standard deviation) or as
median (range), unless stated otherwise.
TOSCA was designed and conducted according to the
Guidelines for Good Clinical Practice and ethical principles
outlined in the Declaration of Helsinki (28, 29). After appropriate
approval by central and all local human research ethics
committees, written informed consent was obtained from all
patients, parents, or guardians prior to enrollment.
RESULTS
As of September 30, 2015, 2,216 patients (1,154 females and
1,062 males) with TSC were enrolled in the TOSCA registry
from 170 sites across 31 countries. The demographic and clinical
characteristics of the enrolled patients are shown in Table 1. The
majority of these patients (70%) were enrolled by pediatric or
adult neurologists.
Overall, SEGA were reported in 554 patients (25%); 275
(49.6%) were males and 279 (50.4%) were females. Of these,
SEGA were present at baseline in 463 patients (83.6%), resolved
with treatment before baseline in 80 patients (14.4%), and were
reported to have resolved spontaneously in 10 patients (1.8%),
the latter possibly due to measurement errors in small lesions.
Detailed information was lacking for one patient. The median
age at SEGA diagnosis was 8 years (range, <1–51 years). SEGA
were diagnosed before 2 years of age in 26.6%, before 18 years in
81.9% of patients, and after 18 years in 18.1% patients (Figure 1).
The oldest patient diagnosed with SEGA in the TOSCA cohort
was 51 years.
Of the 463 patients with SEGA at baseline, 209 (45.1%) had
multiple SEGA and in 208 patients (44.9%) SEGA were present
bilaterally (Table 2). Among patients with SEGA present at the
at the time of baseline visit, SEGA growth was observed in 68
out of 300 patients aged ≤ 18 years (22.7%) and 19 out of 163
patients aged > 18 years (11.6%). In total, 87 out of 463 patients
showed SEGA growth since previous scan (18.8%). Of these, 7
patients (8%) were aged < 2 years, 68 patients (78.2%) were
TABLE 1 | Demographics and clinical characteristics of participants in the TOSCA
study (N = 2,216).
Characteristics Baseline data
Age at diagnosis of TSC, years; median (range) 1 (<1–69)
Gender, n (%)
Male 1,062 (47.9)
Female 1,154 (52.1)
Patients with molecular testing, n (%) 1,000 (45.1)
Genetic testing, n (%)a
No mutation identified 144 (14.4)
TSC1 mutationb 197 (19.7)
TSC2 mutationb 644 (64.4)
Both TSC1 and TSC2 mutations 6 (0.6)
Variation type, n (%)c
Pathogenic mutation 678 (67.8)
Variant of unknown significance 66 (6.6)
Patients with prenatal diagnosis, n (%) 144 (6.5)
TSC, tuberous sclerosis complex; TOSCA, TuberOus SClerosis registry to increase
disease Awareness.
a Information on the type of mutation was missing for 9 patients.
bThe count (n) includes 6 patients who had both TSC1 and TSC2 mutations.
cThe count (n) includes 23 patients who had both variation types.
aged ≤ 18 years, while 19 patients (21.8%) were aged > 18 years.
The median time between consecutive scans was 1 year (mean
1.5 years, range <1–18). At the time of assessment, 321 patients
(69.3%) were asymptomatic. Of these, 29 (9.0%) were aged <2
years, 175 (54.5%) were> 2 years and≤ 18 years, and 117 (36.4%)
were aged> 18 years (Table 3). One or more symptoms (alone or
in combination) assigned to SEGA in our cohort were observed
in 233 patients (50.3%). The most frequent symptoms were
increased seizure frequency in 73 patients (15.8%), behavioural
disturbance in 55 (11.9%), regression/loss of cognitive skills in 46
(9.9%), and headache in 39 (8.4%) (Table 2).
The characteristics of SEGA associated with mutations in
TSC1 and TSC2 are shown in Table 2. SEGA were significantly
more frequently observed in patients with a TSC2 mutation
compared to those with a TSC1 mutation (33.7 vs. 13.2%,
p < 0.0001). However, there was no significant difference with
respect to SEGA diagnosis before 2 years of age (p = 0.3812),
multiple (p = 0.8368), bilateral (p = 0.9550) or growing SEGA
(p= 0.3302), and presence of SEGA-related symptoms (p> 0.05)
in patients with mutations in TSC1 compared to TSC2 (Table 2).
A total of 208 patients received at least one treatment after SEGA
diagnosis with a median time from SEGA diagnosis to treatment
of 319 days (range, 1–5517 days). The most common treatment
modalities included surgical resection (124 patients, 59.6%),
mTOR inhibitors (102 patients, 49%), and ventriculoperitoneal
shunt (22 patients, 10.6%), used alone or in combination.
DISCUSSION
Together with cortical tubers, white matter radial migration
lines, and subependymal nodules, SEGA represent one of the
three major central nervous system features in the diagnostic
criteria for TSC (30). Although benign and slow growing,
SEGA are potentially lethal and can cause serious neurological
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FIGURE 1 | Proportion of patients with SEGAs according to age at SEGA diagnosis (n = 542).
TABLE 2 | Clinical characteristics of SEGA at baseline visit in overall population and according to mutation type.
Overall
(N = 2,216)
Patients with TSC2
mutation (n = 644)
Patients with TSC1
mutation (n = 197)
p-valuec
Patients with a history of SEGAa 554 (25.0) 217 (33.7) 26 (13.2) <0.0001
Median age at diagnosis, yearsb; median (range) 8 (<1–51) 7.0 (<1–49) 7.0 (<1–51) 0.6167
No. of patients diagnosed with SEGA at <age 2 yearsa 144 (26.6) 67 (31.2) 5 (20.8) 0.3812
No. of patients with SEGA present at the time of visit, na 463 185 20 0.2472
Multiple 209 (45.1) 90 (48.6) 8 (40.0) 0.8368
Bilateral 208 (44.9) 84 (45.4) 7 (35.0) 0.9550
Growing SEGA since previous scan 87 (18.8) 35 (18.9) 1 (5.0) 0.3302
Signs and symptoms assigned to SEGAa
None 321 (69.3) 125 (67.6) 11 (55.0) 0.1960
Increase in seizure frequency 73 (15.8) 38 (20.5) 4 (20.0) 1.0000
Behavioural disturbance 55 (11.9) 25 (13.5) 3 (15.0) 0.7311
Regression/loss of cognitive skills 46 (9.9) 20 (10.8) 1 (5.0) 0.6996
Headache 39 (8.4) 15 (8.1) 4 (20.0) 0.0854
Ventriculomegaly 25 (5.4) 9 (4.9) 1 (5.0) 1.0000
Increased intracranial pressure 24 (4.6) 8 (4.3) 3 (15.0) 0.0710
Sleep disorder 14 (3.0) 7 (3.8) 0 1.0000
Eye movement abnormalities 13 (2.8) 6 (3.2) 1 (5.0) 0.5028
Visual impairment 8 (1.7) 4 (2.2) 0 1.0000
Papilledema 8 (1.7) 5 (2.7) 1 (5.0) 0.4498
Neuroendocrine dysfunction 6 (1.3) 3 (1.6) 0 1.0000
Other 14 (3.0) 5 (2.7) 2 (10.0) 0.1313
aChi-square or Fisher exact test.
bMedian test showing comparison of SEGA characteristics between those with TSC1 mutations and TSC2 mutations.
cTSC1 vs. TSC2 at baseline.
SEGA, subependymal giant cell astrocytoma.
complications including raised intracranial pressure due to
obstructive hydrocephalus (7). However, to date, studies on the
natural history of SEGA and TSC have been sparse, smaller in
scale, and typically from a single centre (6). The TOSCA disease
registry has collected disease information on the largest cohort of
patients with TSC to date.
In the current study, SEGA was reported in 25% of patients
with TSC enrolled in the study; of whom, ∼45% had bilateral
SEGA. Most studies have reported lower rates of SEGA in
patients with TSC ranging from 4 to 20% (2, 7–11). The method
used for diagnosis of SEGA in these studies varied substantially.
The highest rates reported to date came from a case series of 214
patients with TSC, which reported SEGA in 20% of their patients
(2). In this study, SEGA was defined as a subependymal lesion
near the foramen of Monro showing contrast enhancement after
administration of intravenous gadolinium. No specifications on
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TABLE 3 | Clinical characteristics of SEGA at baseline visit according to age categories.
Age at TOSCA consent, years
≤2
(n = 283)
>2–≤5
(n = 301)
>5–≤9
(n = 335)
>9–≤14
(n = 307)
>14–≤18
(n = 184)
>18–≤40
(n = 579)
>40
(n = 227)
Patients with a history of SEGA 43 (15.2) 51 (16.9) 98 (29.3) 98 (31.9) 68 (37.0) 167 (28.8) 29 (12.8)
No. of patients with SEGA present at the
time of visit, n
41 (14.5) 45 (15.0) 82 (24.5) 78 (25.4) 54 (29.3) 139 (24.0) 24 (10.6)
Multiple 14 (4.9) 13 (4.3) 35 (10.4) 31 (10.1) 20 (10.9) 53 (9.2) 6 (2.6)
Bilateral 13 (4.6) 13 (4.3) 33 (9.9) 31 (10.1) 20 (10.9) 51 (8.8) 9 (4.0)
Growing SEGA since previous scan 7 (2.5) 9 (3.0) 19 (5.7) 19 (6.2) 14 (7.6) 19 (3.3) 0
Signs and symptoms
None 29 (10.2) 37 (12.3) 61 (18.2) 48 (15.6) 29 (15.8) 97 (16.8) 20 (8.8)
Increase in seizure frequency 8 (2.8) 7 (2.3) 10 (3.0) 13 (4.2) 12 (6.5) 22 (3.8) 1 (0.4)
Behavioural disturbance 3 (1.1) 3 (1.0) 13 (3.9) 10 (3.3) 5 (2.7) 20 (3.5) 1 (0.4)
Regression/loss of cognitive skills 5 (1.8) 3 (1.0) 6 (1.8) 8 (2.6) 9 (4.9) 14 (2.4) 1 (0.4)
Headache 0 1 (0.3) 3 (0.9) 8 (2.6) 10 (5.4) 15 (2.6) 2 (0.9)
Ventriculomegaly 3 (1.1) 0 4 (1.2) 7 (2.3) 4 (2.2) 7 (1.2) 0
Increased intracranial pressure 0 1 (0.3) 2 (0.6) 5 (1.6) 6 (3.3) 8 (1.4) 2 (0.9)
Sleep disorder 2 (0.7) 2 (0.7) 0 6 (2.0) 0 4 (0.7) 0
Eye movement abnormalities 1 (0.4) 1 (0.3) 1 (0.3) 3 (1.0) 2 (1.1) 5 (0.9) 0
Visual impairment 0 0 2 (0.6) 1 (0.3) 1 (0.5) 4 (0.7) 0
Papilledema 0 0 1 (0.3) 1 (0.3) 2 (1.1) 3 (0.5) 1 (0.4)
Neuroendocrine dysfunction 0 0 2 (0.6) 0 1 (0.5) 3 (0.5) 0
Other 0 0 2 (0.6) 6 (2.0) 1 (0.5) 5 (0.9) 0
Percentages were calculated using number of patients in each age group as denominator. SEGA, subependymal giant cell astrocytoma.
size or growth were taken into consideration, which is in line with
the TOSCA cohort. Most of the patients in TOSCA were enrolled
from specialist neurology centres, which might have influenced
the number of patients with SEGA included in TOSCA. We
also have no data on the number of patients who declined to
participate in TOSCA. It cannot be excluded that patients with
milder disease were less likely to participate. In addition, patient
with milder disease might be less likely to have SEGA, potentially
contributing to selection bias.
Published data reported a preponderance of SEGA in children
and adolescents (2, 4, 7, 10). In TOSCA, most SEGA were
indeed diagnosed in childhood, with a median age at SEGA
diagnosis of 8 years. Importantly, 26.6% of patients were
diagnosed with SEGA before 2 years of age (Figure 1), and
growing SEGA were observed in 2.5% of patients aged <2
years (Table 3), highlighting the need for early monitoring.
The potential occurrence of early SEGA growth has been
highlighted previously. The study reported SEGA surgery before
the age of 3 years in 9.4% of total 57 children enrolled in the
study (31).
Prior reports of SEGA growth after the age of 25 years have
been very rare (32). Surprisingly, we identified growing SEGA in
19 patients (2.4%) beyond the age of 18 years. This underlines
the need to remain vigilant in adult patients with known SEGA
as pointed out in the international recommendations for the
surveillance and management of TSC (6, 20). The international
consensus panel recommended performing brain imaging every
1–3 years until the age of 25 years. In TOSCA, the median time
between scans for SEGA follow-up was 1 year (range, 0–18 years),
which is in line with the international recommendations (6, 20).
The frequency of scans within the recommended range of every
1–3 years needs to be determined based on clinical grounds,
with scans performed more frequently in asymptomatic SEGA
patients who are younger, whose SEGA are larger or growing,
or who have developmental delays or intellectual disability.
Individuals without SEGA by the age of 25 years seem not to need
continued imaging (20). For those with SEGA at age 25 years,
follow-up MRI intervals may be increased provided the patient
remains clinically stable.
New onset of symptoms related to raised intracranial pressure
as well as increase in seizure frequency or change in neurological
status and behaviour or loss of skills (especially in patients with
intellectual disability) should trigger an earlier scan. Similarly,
a growing SEGA should prompt a more frequent clinical and
radiological follow-up. Parents and patients should be educated
regarding relevant symptoms that should prompt referral to
medical evaluation (6). The TOSCA data suggest that SEGA-
related symptoms (especially early symptoms) are not exclusively
limited to signs of increased intracranial pressure.
Previous studies suggested that TSC2mutations are associated
with a more severe clinical phenotype (8, 19). Findings from
TOSCA confirmed that SEGA were present more frequently in
patients with mutations in TSC2 compared to TSC1.However,
differences in age at onset, SEGA growth or SEGA-related
symptoms were not significant. The reason for this observation
remains unclear.
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In the current study, surgical resection (59.6%) and mTOR
inhibitor (49%) were the most common treatment modalities
at baseline. Current international recommendations propose
the use of surgical resection for acutely symptomatic SEGAs.
For growing but asymptomatic SEGA, both surgical resection
and mTOR inhibitors are potential treatments. In determining
the best option, discussion of the complication risks, adverse
effects, cost, length of treatment, family preference, surgical
expertise in SEGA, and potential impact on TSC-associated
comorbidities should be included in the decision-making process
(20, 33). mTOR inhibitors have been shown to be effective in
the treatment of other TSC manifestations including epilepsy,
renal angiomyolipoma, and lymphangioleiomyomatosis (22–25).
Hence, the treatment with mTOR inhibitors may be preferred
over surgery in patients with multiple organ involvement or with
a combination of mTOR inhibitor-responsive lesions. mTOR
inhibitors are also recommended for patients with large or
bilateral SEGA that are not amenable to surgical resection (33).
SEGA are likely to regrow in case of incomplete resection.
This was illustrated in a study of 57 patients with TSC who
underwent a total of 64 SEGA surgeries. Gross total resection
was performed in 58 cases with no regrowth, while 5 out of
6 children who underwent partial resection showed tumour
regrowth within 3–12 months (31). It is also important to
consider that long-term mTOR inhibitor treatment may be
required, as discontinuation of mTOR inhibitors is typically
associated with regrowth of tumours (21).
The median time from SEGA diagnosis to treatment initiation
was 319 days. This likely reflects a watch and wait approach to
document growth and the need for intervention.
The current study has the following limitations: firstly, the
observational nature allowed collection of only those data that
were already available from clinical practice and hence reflects
“real world” data. Secondly, amajor challenge for this registry was
to ensure that data about all the disease manifestations for each
patient were reported although the sites involved in the registry
did not always follow patients for all disease manifestations in the
same way. However, the low number of missing data for SEGA
(4.7%) reflects good quality of data collection.
CONCLUSION
In summary, the study highlights that the rates of SEGA
in patients with TSC might be higher than previously
reported. Increase in seizure frequency, behavioural disturbance,
regression/loss of cognitive skills were identified as frequent
symptoms associated with SEGA, over and above headaches,
typically associated with raised intracranial pressure. SEGA may
already be present and grow at a very young age. Although SEGA
mostly occur in childhood, it is important to be vigilant in adults
as well, since SEGA growth does occur also in these age groups.
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